Philipp Diebolder, PhD

Dr. Diebolder is an expert in Antibody Engineering and joined the Rogers Lab in 2015 working as a Postdoctoral Researcher. Born and raised in beautiful Southern Germany, Dr. Diebolder studied Technical Biology at University in Stuttgart (Germany) and received his diploma degree in 2009 (equivalent to combined Bachelor’s and Master’s degree). Impressed by their amazing potential, he early specialized in developing recombinant antibody therapeutics. Dr. Diebolder conducted his Bachelor’s equivalent thesis working on engineered recombinant antibody fragments in the lab of Dr. Andreas Plückthun at University of Zürich (Switzerland) in 2007. His Master’s equivalent thesis was focused on generating antibody-based fusion proteins and bispecifics to activate tumor-specific T-cell response and was performed in the lab of Dr. Roland Kontermann at University of Stuttgart in 2009. Dr. Diebolder received his Ph.D. degree (Dr. rer. nat.) from University of Stuttgart in 2014 working in the research group of Dr. Jürgen Krauss at the National Center for Tumor Diseases (NCT) in Heidelberg (Germany). His doctoral studies included the design and generation of high-quality and cancer-specific LYNDAL antibody libraries prepared from tumor-draining lymph nodes of head and neck cancer patients to prepare human recombinant antibodies with therapeutic potential. His current research in the Rogers Lab includes generating phage display antibody libraries, protein engineering and production of antibodies and recombinant fragments, and the preclinical development of antibody-based cancer therapeutics and (PET) imaging agents by radiolabeling with radioactive copper and/or zirconium.